New drug combo shows promise for stubborn low-platelet disorder

NCT ID NCT05438875

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 26 times

Summary

This study tested whether adding ATRA to the standard drug eltrombopag works better than eltrombopag alone for adults with immune thrombocytopenia (ITP) that did not respond to steroids. ITP causes low platelet counts, leading to bleeding risks. The trial enrolled 96 participants and measured how many achieved a stable platelet count without bleeding for 18 months. The goal is to find a more effective treatment option for this challenging condition.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PURPURA, THROMBOCYTOPENIC, IDIOPATHIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Beijing Tongren hospital

    Beijing, Beijing Municipality, China

  • Department of Hematology, Beijing Friendship Hospital, Capital Medical University

    Beijing, China

  • Department of Hematology, Beijing Hospital

    Beijing, China

  • Department of Hematology, Senior Department of Hematology, the Fifth Medical Center of PLA General Hospital

    Beijing, China

  • Peking University Insititute of Hematology, Peking University People's Hospital

    Beijing, Beijing Municipality, 100010, China

Conditions

Explore the condition pages connected to this study.